• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Can GE HealthCare Technologies (GEHC) Be Undervalued As It Raises Its Dividend And Refreshes Its Board?

    Simply Wall St·09/25/2026 09:24:11
    Listen to the news

    GE HealthCare Technologies (GEHC) just raised its quarterly dividend by 14% to $0.04 per share and added AT&T CFO Pascal Desroches to its Board, moves that directly target income and governance focused investors.

    GE HealthCare Technologies has been active on several fronts in recent weeks, from the planned Sofie Biosciences acquisition and the launch of its CareIntellect for Operations AI platform to the dividend hike and board refresh you just saw.

    Even with that activity, the shares trade at $66.38 and the year-to-date share price return is down 19.85%, with a 30-day share price return down 9.45%, although the 7-day share price return of 3.51% hints at some improving short-term momentum.

    Over a longer horizon, the total shareholder return is down 8.22% over one year and down 1.93% over three years, which gives important context if you are weighing whether the richer dividend and fresh governance experience change the risk-reward balance for GE HealthCare Technologies.

    Scan how other income and healthcare-focused opportunities compare with GE HealthCare Technologies by reviewing our hand picked 38 healthcare AI stocks.

    For GE HealthCare Technologies, a richer dividend and a high profile board addition can either reflect confidence in the underlying franchise or simply catch a sentiment bounce. Which story do the current valuation markers tell?

    Most Popular Narrative: 20% Undervalued

    On the most followed view of GE HealthCare Technologies, a fair value of $82.50 set against the $66.38 last close suggests the market is not fully pricing in its cash flow potential, even after the recent dividend increase and governance changes.

    The focus on expanding recurring revenue, particularly in areas like digital solutions and advanced visualization, now includes multi year equipment plus service alliances such as the approximately US$500 million Catholic Health Care agreement and rising service backlog, which together increase revenue visibility and can support steadier net margins.

    See why 74 investors see GE HealthCare Technologies as 20% undervalued.

    Result: Fair Value of $82.50 (UNDERVALUED)

    Still, tariff pressure on input costs and prolonged weakness in Patient Care Solutions could quickly challenge the idea that GE HealthCare Technologies is 20% undervalued.

    Find out about the key risks to this GE HealthCare Technologies narrative.

    Next Steps

    If the split view on GE HealthCare Technologies leaves you undecided, move quickly to review the full risk and reward picture. Then make your own judgment using the 4 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond GE HealthCare Technologies?

    If you like what GE HealthCare Technologies is doing but want a wider opportunity set, let a few focused stock lists show you where else to look.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.